

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
June 24, 2014**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES ACT OF 1933**

Kite Pharma, Inc.

File No. 333-196081 - CF#30957

Kite Pharma, Inc. submitted an application under Rule 406 requesting confidential treatment for information it excluded from the Exhibits to a Form S-1 registration statement filed on May 19, 2014, as amended.

Based on representations by Kite Pharma, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 10.17	through April 4, 2017
Exhibit 10.18	through April 4, 2017
Exhibit 10.19	through June 1, 2017
Exhibit 10.20	through April 4, 2017

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Kevin M. O'Neill
Deputy Secretary